1. Scrip

Mirum Targets $500m Sales For Just-Approved Rare Liver Disorder Drug

FDA Green Light For Alagille Syndrome Therapy Livmarli

 
• By Kevin Grogan

Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.

false start
Mirum quick out of the blocks with Livmarli launch

Mirum Pharmaceuticals, Inc. is ready to hit the ground running after clinching the green light in the US for Livmarli, the first medication for the rare liver disease Alagille syndrome (ALGS).

The US Food and Drug Administration has approved Livmarli (maralixibat) for the treatment of cholestatic pruritus in children with ALGS, a rare genetic disorder in which bile ducts are abnormally narrow, malformed and reduced in number, which leads to bile accumulation in the liver

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.